Study of the correlation between H-ras mutation and primary hepatocellular carcinoma
- Authors:
- Guode Sui
- Xuexiao Ma
- Shiguo Liu
- Haitao Niu
- Qian Dong
View Affiliations
Affiliations: Department of Emergency General Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Department of Spinal Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Gout Laboratory, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Department of Urology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Department of Pediatric Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China
- Published online on: July 27, 2012 https://doi.org/10.3892/ol.2012.832
-
Pages:
779-782
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of this study was to investigate the correlation between H-ras mutation and primary hepatocellular carcinoma (HCC) and to describe the role of H-ras mutation in carcinogenesis. Clinical samples of 69 patients were collected and the expression levels of H-ras in HCC and the surrounding normal tissues were examined using HotStarTaq PCR. H-ras mutation was further analyzed using the PCR direct sequencing method. The results showed that H-ras mutation was present in 49 samples (49/69, 71.01%), of which 19 had codon 40 mutated from CTA to CTG and 30 had codon 61 mutated from GGC to AGC. By contrast, only 2 mutations were found in the normal tumor-adjacent tissues. The H-ras mutation rate in the high-risk of metastatic recurrence group was markedly higher than that in the low-risk group (P<0.01). The H-ras mutation rate in patients with metastatic recurrence during postoperative follow-up was also significantly higher than that in patients without metastatic recurrence (P<0.01). Based on the above results, the H-ras mutation frequency in cancer tissues is markedly higher compared with that in normal tissues. H-ras mutation may play an important role in the genesis and development of HCC and may serve as a reliable marker for individual comprehensive therapy in HCC.
View References
1.
|
JM LukAM LiuProteomics of hepatocellular
carcinoma in Chinese
patientsOMICS15261266201110.1089/omi.2010.009921348761
|
2.
|
T YangJ ZhangJH LuLQ YangGS YangMC WuWF
YuA new staging system for resectable hepatocellular carcinoma:
comparison with six existing staging systems in a large Chinese
cohortJ Cancer Res Clin
Oncol137739750201110.1007/s00432-010-0935-320607551
|
3.
|
M DaviesSS PrimeJW EvesonN PriceA
GanapathyA D’MelloIC PatersonTransforming growth factor-β enhances
invasion and metastasis in Ras-transfected human malignant
epidermal keratinocytesInt J Exp Pathol931481562012
|
4.
|
Y Gus-BrautbarD JohnsonL ZhangH SunP WangS
ZhangL ZhangYH ChenThe anti-inflammatory TIPE2 is an inhibitor of
the oncogenic RasMol
Cell45610618201210.1016/j.molcel.2012.01.00622326055
|
5.
|
JH OvermeyerWA MalteseDeath pathways
triggered by activated Ras in cancer cellsFront
Biosci1616931713201110.2741/381421196257
|
6.
|
JM CullenC WilliamsL ZadroznyJT OtstotGG
SolomonRC SillsHH HongH-ras consensus sequence and mutations in
primary hepatocellular carcinomas of lemurs and lorisesVet
Pathol48868874201110.1177/030098581038852621123858
|
7.
|
XD ZhouRecurrence and metastasis of
hepatocellular carcinoma: progress and prospectsHepatobiliary
Pancreat Dis Int13541200214607620
|
8.
|
S ReginaJ RollinC BléchetS IochmannP
ReverdiauY GruelTissue factor expression in non-small cell lung
cancer: relationship with vascular endothelial growth factor
expression, microvascular density, and K-ras mutationJ Thorac
Oncol3689697200810.1097/JTO.0b013e31817c1b21
|
9.
|
Q ZuoH HuangM ShiF ZhangJ SunJ BinY LiaoW
LiaoMultivariate analysis of several molecular markers and
clinicopathological features in postoperative prognosis of
hepatocellular carcinomaAnat Rec
(Hoboken)295423431201210.1002/ar.21531
|
10.
|
MJ HoenerhoffI ChuD BarkanZY LiuS DattaGP
DimriJE GreenBMI1 cooperates with H-RAS to induce an aggressive
breast cancer phenotype with brain
metastasesOncogene2830223032200910.1038/onc.2009.16519543317
|
11.
|
HW LoTargeting Ras-RAF-ERK and its
interactive pathways as a novel therapy for malignant gliomasCurr
Cancer Drug
Targets10840848201010.2174/15680091079335797020718706
|
12.
|
G BuhrmanC O’ConnorB ZerbeBM KearneyR
NapoleonEA KovriginaS VajdaD KozakovEL KovriginC MattosAnalysis of
binding site hot spots on the surface of Ras GTPaseJ Mol
Biol413773789201110.1016/j.jmb.2011.09.01121945529
|
13.
|
M NakamuraJ KitauraY EnomotoY LuK
NishimuraM IsobeK OzakiY KomenoF NakaharaT OkiTransforming growth
factor-β-stimulated clone-22 is a negative-feedback regulator of
Ras/Raf signaling: Implications for tumorigenesisCancer
Sci10326332012
|
14.
|
M LeeDifferential physiological effects of
Raf-1 kinase pathways linked to protein kinase C activation
depending on the stimulus in v-H-ras-transformed cellsCancer Res
Treat403944200810.4143/crt.2008.40.2.39
|
15.
|
X YinBH ZhangSJ QiuZG RenJ ZhouXH ChenY
ZhouJ FanCombined hepatocellular carcinoma and cholangiocarcinoma:
clinical features, treatment modalities, and prognosisAnn Surg
OncolMar272012(Epub ahead of print)
|